Stroke prevention in patients with non-valvular atrial fibrillation: A current community perspective

Journal of Clinical Neuroscience

Volumn 4, Issue 3, 1997, Pages 320-325

  Enis, Joseph ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

Anticoagulation; Clinical practice; Non valvular atrial fibrillation; Stroke prevention

Indexed keywords

EID: 0009468967     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(97)90099-0     Document Type: Article

References (71)

1. Martin R, Bogousslavsky J. Embolic versus nonembolic causes of ischemic stroke. Cerebrovasc Dis 1995; 5: 70-74.
2. Caplan LR. Clinical diagnosis of brain embolism. Cerebrovasc Dis 1995; 5: 79-88.
3. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 1986; 43: 71-84.
4. Whisnant JP. Probability of stroke after transient ischaemic attack. In: Whisnant JP (ed). Stroke: Populations, Cohorts and Clinical Trials. London: Butterworth Heinemann 1993; 141-143.
5. Wolf PA, Kannel WB, Verier J. Current status of risk factors for stroke. Neurol Clin 1983; 1: 317-343.
6. Wolf PA, Kannel WB, McGee DL et al. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke 1983; 14: 664-667.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-988.
8. Fisher CM. Stroke (letter). Lancet 1992; 339: 112-113.
9. Hinton RC, Kistler JP, Fallon JT, Friedlich AL, Fisher CM. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol 1977; 40: 509-513.
10. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469-473.
11. Rowland D. Ageing in Australia. Melbourne: Longman, 1992.
12. Grant C. The Australian health care system 1991. Sydney: University of NSW, 1992.
13. Wellens HJJ. Atrial fibrillation: the last big hurdle in treating supraventricular tachycardia. N Engl J Med 1994; 331: 944-945.
14. Fisher CM. Reducing risks of cerebral embolism. Geriatrics 1979; Feb: 59-66.
15. Harrison MJG, Marshall J. Atrial fibrillation, TIAs and completed strokes. Stroke 1984; 15: 441-442.
16. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke 1996; 27: 1760-1764.
17. Enis J, Tagkalidis A. Current use of anticoagulants to prevent cardiac embolic stroke in patients with non-valvular atrial fibrillation (abstract). J Clin Neurosci 1995; 2: 98.
18. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1: 175- 179.
19. The Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
20. Stroke prevention in atrial fibrillation investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527-539.
21. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-355.
22. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
23. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-1457.
24. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994; 154: 1443-1448.
25. EAFT (European atrial fibrillation trial) study group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
26. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
27. North American symptomatic carotid endarterectomy trial collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445-453.
28. Stroke prevention in atrial fibrillation investigators. A differential effect of aspirin on prevention of stroke in atrial fibrillation. J Stroke Cerebrovasc Dis 1993; 3: 181-188.
29. Stroke prevention in atrial fibrillation investigators. Predictors of thromboembolism in atrial fibrillation: 1. clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
30. Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21: 4-13.
31. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108 (Suppl): 352-359.
32. Koudstaal PJ. Anticoagulation in very elderly patients (>80 years) with stroke and atrial fibrillation. Cerebrovasc Dis 1995; 5: 8-9.
33. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulant and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151: 1950- 1953.
34. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 277-281.
35. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-328.
36. Fihn SD, McDonell M, Martin D et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118: 511-520.
37. Loeliger EA, van Dijk-Weirda CA, van den Besselaar AMHP, Broekmans AW, Roos J. Anticoagulant control and the risk of bleeding. In: Mead TW (ed). Anticoagulants and Myocardial Infarction: A Reappraisal. London: John Wiley and Sons, 1984: 135-177.
38. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153: 1557-1562.
39. Landefeld CS, Goldman L. Major bleeding in outpatients with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
40. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991; 229: 351-355.
41. Roos J, van Joost HE. The cause of bleeding during anticoagulant treatment. Acta Med Scand 1965; 178: 129-131.
42. Pollard JW, Hamilton MJ, Christensen NA, Achor RWP. Problems associated with long-term anticoagulant therapy. Circulation 1962; 25: 311-317.
43. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med 1988; 148: 1733-1736.
44. Wickramasinghe LSP, Basu SK, Bansal SK. Long-term oral anticoagulant therapy in elderly patients. Age Ageing 1988; 17: 388-396.
45. Petty GW, Lennihan L, Mohr JP et al. Complications of long-term anticoagulation. Ann Neurol 1988; 23: 570-574.
46. Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982; 1: 64-68.
47. Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: experience with an anticoagulation clinic. Arch Intern Med 1984; 144: 1966-1968.
48. Adams JN, Gautam PC. Anticoagulant therapy in elderly patients. J Clin Exp Gerontol 1992; 14: 183-196.
49. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-733.
50. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995; 26: 1471-1477.
51. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
52. Brott T, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke 1986; 17: 1078- 1083.
53. Wintzen AR, de Jonge H, Loeliger EA, Bots GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984; 16: 553-558.
54. EAFT Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10.
55. Stroke prevention in atrial fibrillation investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687-691.
56. Connolly S for the atrial fibrillation investigators. Stroke prevention in atrial fibrillation 2 study (letter). Lancet 1994; 343: 1509.
57. Stroke prevention in atrial fibrillation investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409-416.
58. Hirsh J. Oral anticoagulant drugs. N EnglJ Med 1991; 324: 1865-1875.
59. Saour J, Gallus A. Warfarin: is it time to reduce target ranges again? Aust NZJ Med 1993; 23: 692-696.
60. Major ongoing stroke trials Stroke 1995; 26: 1978-1982.
61. Stroke prevention in atrial fibrillation investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
62. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546.
63. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Ageing and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: 901-904.
64. Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in patients with atrial fibrillation. Br Med J 1993; 307: 1045.
65. Gariballa SE, Robinson TG, Parker SG, Castleden CM. A prospective study of primary and secondary risk factor management in stroke patients. J Roy Coll Physicians Lond 1995; 29: 485-487.
66. Lip GYH, Zarifis J, Watson RDS, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart 1996; 75: 200-205.
67. Gottleib LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945-1953.
68. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke L Cost-effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. Br Med J 1992; 305: 1457-1460.
69. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839-1845.
70. Ramsay LE. Cardiovascular disease: warfarin in chronic atrial fibrillation. Lancet 1993; 341: 1376-1377.
71. Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995; 155: 2185-2189.